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Abstract:  Neuromolecular Imaging (NMI) with novel biosensors enables the selective 
detection of neurotransmitters in vivo within seconds, on line and in real time. Biosensors 
remain in place for continuing studies over a period of months. This biotechnological 
advance is based on conventional electrochemistry; the biosensors detect neurotransmitters 
by electron transfer. Simply stated, biosensors adsorb electrons from each neurotransmitter 
at specific oxidation potentials; the current derivd from electron transfer is proportional to 
neurotransmitter concentration. Selective electron a sfer properties of these biosensors 
permit the imaging of neurotransmitters, metabolites and precursors. The novel 
BRODERICK PROBE® biosensors we have developed, differ in formulation and detection 
capabilities from biosensors/electrodes used in conventional electrochemistry/ 
voltammetry. In these studies, NMI, specifically, the BRODERICK PROBE® laurate 
biosensor images neurotransmitter signals within  mesolimbic neuronal terminals, nucleus 
accumbens (NAc); dopamine (DA), serotonin (5-HT), homovanillic acid (HVA) and L-
tryptophan (L-TP) are selectively imaged.  Simultaneously, we use infrared photobeams to 
monitor open-field movement behaviors on line with NMI in the same animal subjects. The 
goals are to investigate integrated neurochemical and behavioral effects of cocaine and 
caffeine alone and co-administered and further, to use ketanserin to decipher receptor 
profiles for these psychostimulants, alone and co-administered. The   rationale for selecting 
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this medication is: ketanserin (a) is an antihypertensive and cocaine and caffeine produce 
hypertension and (b) acts at 5-HT2A/2C receptors, prevalent in NAc and implicated in 
hypertension and cocaine addiction.  Key findings are: (a) the moderate dose of caffeine 
simultaneously potentiates cocaine's neurochemical and behavioral responses. (b) 
ketanserin simultaneously inhibits cocaine-increased DA and 5-HT release in NAc and 
open-field behaviors and (c) ketanserin inhibits 5-HT release in NAc and open-field 
behaviors produced by caffeine, but, surprisingly, acts to increase DA release in NAc.  
Importantly, the latter effect may be a possible adverse effect of the moderate dose of 
caffeine in hypertensive patients. Thus, an antihypertensive medication is shown here to 
play a role in inhibiting brain reward possibly via antihypertensive mechanisms at DA and 
5-HT receptor subtypes within DA motor neurons.  An explanatory note for the results 
obtained, is the role likely played  by the G Protein Receptor Complex (GPRC) family of 
proteins. Empirical evidence shows that GPRC dimers, heteromers and heterotrimers  may 
cause  cross-talk between distinct signalling cascade pathways in the actions of cocaine and 
caffeine. Ligand-directed functional selectivity, particularly for ketanserin, in addition to 
GPRCs, may also cause differential responses. The results promise new therapeutic 
strategies for drug addiction, brain reward and cariovascular medicine.  
Keywords: anxiety, brain, caffeine, cocaine, dopamine, electrochemistry, G-protein 
receptor complexes (GPRC), homovanillic acid, hypertension, ketanserin, L-tryptophan, 
mesolimbic, motor tracts, neuromolecular imaging, nucleus accumbens, open-field 
behaviors, psychostimulants, serotonin, ventral tegmental area. 
 
1. Introduction 
NMI with BRODERICK PROBE® biosensors selectively detects neurotransmitters, metabolites and 
precursors of neurotransmitters in vivo in DA motor neurons which direct movement behaviors. We 
focused on imaging DA, 5-HT, HVA and L-TP in NAc, while simultaneously monitoring open-field 
behaviors. The specific open-field behaviors studied were: locomotion (forward ambulatory motion), 
stereotypy (repeated grooming motion, also called fine movements) and central locomotion (forward 
ambulatory motion in the central part of the chamber, indicating reduced anxiety). Thus, NMI provides 
a close cause and effect relationship between brain and behavior. Current technologies, e.g., 
microdialysis, are limited because microdialysis devic s can traumatize brain tissue (1).  
We used NMI, based on an electrochemical method of analysis, because NMI provides advantages 
over spectroscopic or chromatographic methods. For example, NMI (a) enhances the specificity, 
selectivity, simplicity and sensitivity of its spectroscopic and chromatographic counterparts, (b) does 
not need pre-/post-assay functional group derivatives and (c) selectively detects neurotransmitters 
within a complex living matrix in vivo.  
The precise focus of our studies in brain is the mesolimbic pathway in the freely moving 
(unrestrained) and behaving animal in vivo. Figure 1 depicts schematically the mesolimbic neuronal 
circuit in brain. We collaborated with Dr. Clyde Phelix, San Antonio, Texas, to perform 




immunocytochemical studies that show a significant overlap in the presence of DA and 5-HT in DA 
axons in NAc at the site of the BRODERICK PROBE® biosensor (2). Figure 2 shows the 
immunocytochemistry results. It is important to note here that serotonergic cells in 5-HT cell bodies in 
dorsal raphe project axons to NAc; these axons play a critical role in the DA mesolimbic pathway to 
neuromodulate movement behavior (3). 
Figure 1. Human (left) and murine brain (right) depicting mesolimbic and mesocortical 
DA pathways which originate in VTA and send ascending projections to NAc and 
Prefrontal Cortex (PFC). Feelings of reward as well as aversion are derived herein. VTA 
sends descending projections to the tegmental pedunculopontine nucleus (TPP), 
implicated in non-DA mediated reward signalling. (Adapted by permission from 




The aims are to use NMI, BRODERICK PROBE® laurate biosensors and infrared photobeams to (a) 
study in vivo integrated neurochemistry and behavior produced by cocaine and caffeine alone and co-
administered and (b) study the effects of the antihypertensive medication, ketanserin, on cocaine and 
caffeine responses alone and co-administered.  
Cocaine is known to be a reinforcer of psychostimulant behavior (4). Cocaine increases DA 
reuptake inhibition and DA release at the synapse in mesolimbic and nigrostriatal brain reward centers, 
thereby inducing a feeling of “joie de vivre". Cocaine enhances brain reward by pharmacologic 
sensitization, i.e., repeated use causes enhanced reward in part, via adenosine inhibitors (5,6). 
Nonetheless, cocaine produces neuroadaptive withdrawal symptoms and hypertension (4,7). 
Caffeine is known to reinforce psychostimulant behavior, increase DA concentrations in mesolimbic 
and nigrostriatal pathways in brain and has adenosine receptor inhibiting properties (8). Similarly to 
cocaine, caffeine produces withdrawal symptoms and hypertension (9). Unlike cocaine, caffeine 
produces pharmacologic tolerance, i.e., repeated us of caffeine causes diminished responses (9). 
Moreover, unlike cocaine, whose only clinical use i as a local anesthetic, caffeine has been shown 
to have several clinical and possible clinical uses. Caffeine may reduce traumatic brain injury (TBI) in 




animals (10). Caffeine is used clinically to assist breathing in preterm babies and to increase alertness 
and performance in adult patients (11). Recent discoveries about caffeine include a report that caffeine 
may reduce risk of diabetes by 50% (12). Caffeine may protect against Parkinson's Disease (13). 
Ketanserin is an antihypertensive medication (14). Ketanserin binds with (a) 5HT2A/2C receptors, (b) 
histamine, (c) adrenergic (α1) receptors, (d) 5-HT1A receptors in the human (pKi value, 5.9 and 6.2), (e) 
5-HT2B, adrenergic α2 receptors and (f) acetylcholine (Ach)  muscarinic re eptors. Ketanserin does not 
bind to DA receptors (15, 16). In a clinical study, ketanserin blocked adenosine-induced 
bronchospasm, providing a possible link between ketanserin and adenosine receptors (17). We used 
ketanserin to delineate receptor profiles for cocaine and caffeine because this medication selectively 
binds to 5-HT2A/2C receptors, with high affinity, in mesolimbic areas of brain. 
Figure 2. Immunocytographs of DA and 5-HT in NAc (ventrolater l (vl)) of Sprague 
Dawley laboratory rats.  Dark field photomicrographs show the distribution of (A) DA 
neurons, stained with tyrosine hydroxylase; two high density patterns of DA are 
apparent in the medial and lateral core,  (B) 5-HT axons in the caudal one-third of NAc; 
5-HT was stained with a sensitive silver intensification procedure, thus axons and 
terminals are black, (C) 5-HT axons in DA neurons i NAc at the site of the 
BRODERICK PROBE® laurate biosensor. In B, two low density patterns of 5-HT are 
apparent in the ventral and ventrolateral NAc. High density 5-HT is seen in the 
perimeter around the core. (scale-horizontal line shown in bottom left of Fig. 2A=500 
um)(Adapted by permission from Elsevier, Brain Research Bull., 1995, 37, 37-40) (2). 
Direct efferent neurons derive from VTA to vlNAc (90). (D) Coronal section of NAc 
depicting vlNAc (Adapted by permission from Springer, A Stereotaxic Atlas of Rat 
Brain, 1979, 20) (35).  
 





2.1. Conventional Voltammetry and Microvoltammetry 
Significant advances in voltammetry and microvoltammetry have been made with the use of carbon 
fiber and carbon paste biosensors. For example, Nafion® a perflourosulfonated compound, as well as 
ascorbic acid enzyme inhibitors are used as coatings o  biosensors to separate ascorbic acid from DA. 
Also, a subtractogram method is used for interpreting in vivo recordings to separate 5-HT from DA. 
Therefore, brain neurotransmitter studies in vivo have been in progress for quite some time (cf. 18,19 




• Involve measurement of current as a function of applied potential, wherein  
• electroactive species undergo redox reactions at a characteristic redox potential. 
• Formula:O + ne_  ⇔ R, wherein, ne = number of electrons, O=oxidation, R= reduction.  
• The current that is produced by a specific redox reaction is proportional to the concentration of 
neurochemicals, according to the Cottrell equation, described below. 
     
Historically, methods based on conventional voltammetry and microvoltammetry, as pioneered in 
the 1970's, have validated that the flow of charge, i.e., amount of current in amperes, which passes 
through the surface of an indicator electrode is propo tional to the concentration of the electroactive 
species studied (18-20). The following formulas describe this relationship in terms of charge, electron 
transfer, current, diffusion layer, time, Faraday's constant, size of the indicator electrode and 
concentration (mass) of electroactive species.  
 
Q = nFVCoR     i =  dQ/dt    i = nFV dCR,t  / dt 
 
where V is the volume of the diffusion layer on the electrode where the measurement is being made, 
n is the number of electrons transferred, F is the Faraday Constant, and Co denotes initial 
concentration. The Cottrell equation is derived from the formulas written above and demonstrates that 
current i.e., charge and mass, i.e., concentration, are proportional. The Cottrell equation is: 
 
it =  nFACoDo
1/2/3.14 ½ t½ 
where: 
o=concentration of electroactive species oxidized. 
i = current at time, t 
n = number of electron transfers, eq/mol 
F = Faraday’s constant, 96486 C/eq 
A = electrode area, cm 2 
C = concentration of o, mol/cm3 
D = Diffusion coefficient of o, cm2/s 




2.2.  Neuromolecular Imaging (NMI)  
NMI has made significant advances in the field of electrochemical methods. Specifically, (a) 
formulations and detection capabilities of biosensors are different. We embedded a series of saturated 
and unsaturated fatty acid and lipid surfactant assemblies into carbon-paste-based biosensors in a 
variety of concentrations to allow advanced detection capabilities e.g., selective imaging of ascorbic 
acid, DA, 5-HT, HVA, L-TP and peptides, such as dynorphin and somatostatin (21-26), (b) with NMI 
biosensors, there is no need for cumbersome head stages as are needed by conventional i  vivo 
voltammetric and microvoltammetric methods (27,28) because NMI biosensors have low resistance 
properties, (c) NMI biosensors are resistant to bacterial growth (26), (d) Unlike carbon fiber 
biosensors, NMI biosensors do not form gliosis, i.e., scar tissue which impedes detection of 
neurotransmitters, causing electrochemical signals to decay (29) and (e) Like other carbon-paste-based 
biosensors, NMI biosensors respond to the lipid matrix of the brain by enhancing electron transfer 
kinetics; this property improves the sensitivity, selectivity and operational stability of the biosensors, 
allowing the detection of reliable electrochemical signals that are long-lasting (29).  
In this paper, results from NMI laurate biosensors a e presented. Lauric acid has a hydrophobic 
head, hydrophilic tail, and acts as a surfactant to reduce surface tension. The surfactant, lauric acid, 
also acts to assist the migration of molecules to form an oriented, adsorbed film on the interfacial 
surface of the indicator sensor. This mechanism is a key characteristic for electron transfer kinetics 
exhibited by NMI biosensor subtypes. Figure 3 shows a chematic diagram of a BRODERICK 
PROBE® biosensor with specifications. 
Figure 3. Schematic of the generic BRODERICK PROBE®  biosensor with specifications. 
 
Adapted by permission from Elsevier, Brain Research Bull., 1995, 37, 37-40) 
 
 




2.3. Manufacture of Laurate Biosensors 
Laurate biosensors are manufactured on site. Lauric ac d is a saturated fatty acid (formula: 
CH3(CH2)10COOH). Laurate biosensors, for these studies, were comprised of < 1 mg aliquot of stock, a 
mixture of ultra-pure carbon (1.5g), oil (Nujol) containing alpha tocopherol (1.24 g), and lauric acid 
(100 mg). Details of the construction of the laurate biosensor are published (21-25). 
2.4. NMI Properties of Laurate Biosensor 
Oxidation Potentials for these biosensors, in vitro, are, in the order of detection from lowest to 
highest positive potential, ascorbate [0.08 V]; DA [0.13 V]; 5-HT [0.29 V]; HVA [0.43V] and L-TP 
[0.63]. Oxidation Potentials for these biosensors, in vivo, are, in the order of detection from lowest to 
highest oxidation potential, ascorbate [0.09 V], DA[0.14 V], 5-HT [0.31 V]; HVA [0.44V] and L-TP 
[0.64]. Each specified oxidation potential is within a range of +/- 0.015V. 
2.5. Semiderivative Circuit 
During the performance of research in the electrochemical analysis and biosensor field, this 
laboratory has studied and improved electrical circuits for imaging a multifaceted array of 
neurochemicals. Although NMI biosensors can be used with many different voltammetric electrical 
circuits, we primarily, but not exclusively, have worked with one which 
semidifferentiates/semiderivatizes the voltammetric linear ramp circuit. Importantly, we discovered 
that a reduction semiderivative circuit is optimal for oxidizing neurochemicals for this type of analysis 
(22). Further, by studying a variety of capacitors and resistors for use with potentiostats and miniature 
biosensors, we found that either a one second or a five second time constant is optimal for imaging 
neurotransmitters in vivo. 
2.6. Calibration Procedures 
Biosensors are precalibrated in vitro in a freshly made deoxygenated physiological saline-phosphate 
buffer solution (0.01 M, pH=7.4 containing nmol aliquots of DA, 5-HT, norepinephrine (NE) (99% 
purity, Sigma-Aldrich, St. Louis, MO) and several other neurochemicals such as ascorbic acid, uric 
acid, 3,4, dihydroxyphenylacetic acid (DOPAC), HVA, L-TP and peptide neurotransmitters, such as 
dynorphin and somatostatin. The deoxygenation process takes place by purging the electrochemical 
cell with ultra pure nitrogen gas at 10 psi to remove traces of oxygen from air for one minute before the 
biosensor is set to cell mode at the resting potential of 0.2V before anodic scanning begins.  For cell
deposition/equilibration, we allow the resting potential to remain at 0.2 V for two minutes. The E1 
initial potential, resting potential of 0.2 V, is selected so that during the scanning process, non-faradaic, 
charging current is recorded before cathodic and anodic images appear at experimentally derived 
characteristic oxidation potentials. Biosensors are postcalibrated in vitro in a fresh deoxygenated 
physiological saline-phosphate buffer solution, (0.01M, pH=7.4). 
Biosensors can be lipid amplified with phosphotidylethanolamine (PEA) (10% w/v) and bovine 
serum albumin (BSA) (1% w/v). This process takes place for thirty min after which biosensors are 
immersed in saline (0.16 M) for 45 min, and finally biosensors are immersed in saline (0.16 M) 




phosphate (0.01M) buffer (pH 7.4). Results from lipid amplification of laurate biosensors correlates 
with that exhibited by electrodes used to study lauric acid by Raman Spectroscopy (30).  Figure 4A 
depicts baseline in vivo neurochemical images detected by the laurate biosens r. Figures 4 B, C and D 
depict in vivo neurochemical images detected by the laurate biosensor after drug(s).  
 
In vitro images of neurochemicals using the laurate biosensr are published (31). 
Figure 4A. NMI recordings of neurotransmitters in NAc, drawn from raw data of 
baseline DA, 5-HT, HVA and L-TP signals. Figure 4B, C, and D. NMI recordings of 
neurotransmitters, drawn from raw data of DA, 5-HT, VA and L-TP signals after (B) 
caffeine, (C) ketanserin and caffeine and (D) ketanseri , cocaine and caffeine. The y 
axis shows current changes in nanoamperes (nA) frombaseline. The x axis shows 
applied potential in subunits of Volts (millivolts). Each neurochemical exhibits electron 
transfer properties at a specific oxidation potential. Current is proportional to the 
concentration of each neurochemical as described by the Cottrell Equation (18-20). 
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2.7. Interpretation of NMI Signals 
Dopamine and 5-HT have amine groups that are protonated at neutral pH and exist as cations; 
metabolites of the monoamines are not protonated at physiological pH and exist as anions (32). Cations 
are imaged in these studies in vitro and in vivo and anions are detected generally at higher 
concentrations in vitro and in vivo. Detection of anions does not interfere with that of cations because 
each neuromolecule is oxidized at an empirically-derived, specific oxidation potential. Calibration 
curves for DA, 5-HT, L-TP, norepinephrine (NE) and ascorbic acid (AA) are published with an 
extensive treatise on selection separation of these compounds from one another (33,34).  
2.8. Animals and Surgical Procedures:  
These studies are approved by the National Institutes of Health (NIH) in accordance with the 
Institutional Animal Care and Use Committee (IACUC) of The City College New York, The City 
University of New York. To begin these studies, we purchase male, Sprague Dawley, Caesarean-
derived, virus-free, laboratory rats (rattus norvegicus) from Charles River Laboratories, Kingston, NY. 
When the animals arrive at our facility, they are housed in our Marshak Vivarium for about one week 
before surgery begins to allow animals to become acclimated to their environment. Animals are fed 
Purina Rat Chow and water ad libitum. A twelve hour dark-light cycle is maintained both in the 
Vivarium and in Dr. Broderick's research laboratory where studies take place, to maintain animals' 
circadian rhythms.  
Surgery begins with an intraperitoneal (ip) injection of the anesthetic pentobarbital Na (50 mg/kg in 
a dilute 6% solution)). Laurate biosensors are inserted stereotaxically (Kopf Stereotaxic, Tujunga, CA) 
within NAc (AP= +2.5; ML= +2.6; DV= -7.3) (35) and a Ag/AgCl microreference and stainless steel 
microauxiliary are placed in contact with dura. Indicator laurate biosensors are held in place with 
Splintline Acrylic (Lang Dental, Il.). Temperature is continuously monitored with a rectal probe and 
thermometer (Fisher Sci., Fadem, NJ); temperature is maintained at 37.5°C ± 0.5°C with an aquamatic 
K module heating pad (Amer. Hosp. Supply, Edison, NJ). Pinnal, corneal and leg flexion responses are 
monitored throughout surgery and supplemental doses f Na pentobarbital are administered to maintain 
adequate pharmacokinetic induction and depth of anesthesia. Physiologic saline (animal body weight in 
cc's) is injected at the completion of surgery to maintain proper electrolyte and volumetric status. The 
total time for surgery is two to three hrs. Animals re housed individually after surgery and recover 
from surgery with food and water ad lib before the experimental studies begin. 
2.9. Neuromolecular Imaging (NMI) On Line with Open Field Behavior 
Studies are performed in freely moving (unrestrained) animals during movement behavior. Each 
animal is placed in a Plexiglas® faradaic chamber insulated from white light frequency with a copper 
sheath (dimensions: 24" x 18" x 23.5"). The three-biosensor assembly is connected to a CV37 
potentiostat (BAS, West Lafayette, IN) or a computerized Autolab Analyzer (manufactured at 
EcoChemie, Netherlands and distributed by Brinkmann, Westbury, NY). NMI signals are transduced to 
a mercury commutator. (Br. Res. Instr., Princeton, NJ) by a flexible cable, and a mating connector 
(BJM Electronics, Staten Island, NY). Cables are designed and manufactured on site. The potentiostat 




is electrically connected to a Minigard surge suppresser (Jefferson Electric, Magnetek, NY) which is 
connected to an electrical ground in isolation. When the CV37 potentiostat is used, NMI is recorded on 
a strip chart recorder (The Recorder Company, San Marcos, TX). Physiologic steady state for 
electrochemical signals is achieved before drug(s) are administered. Neurochemical data are 
normalized to 100% of control/baseline values.  
NMI signals are imaged at the same time as open-field behaviors are monitored. Figure 5 show   the 
NMI electro-analytical and behavioral device set-up, designed on site. The faradaic chamber in which 
the NMI signals are recorded, is fitted with infrared photobeams set into aluminum frames, placed 3/4 
inches above the chamber’s floor. The infrared photobeams are activated by a Pentium 3 circuit using a 
modified version of the Activity Pattern Monitor (APM) (San Diego Instruments, San Diego. CA). The 
system permits simultaneous and selective monitoring of movements in real time at a resolution 1.5 
inches in 0.1 secs. The animal’s position is based on X-Y axes calculated in terms of one of 16 equally 
sized sectors and one of nine unequally sized regions. Every 100 msec, the computer checks the status 
of all the beams in the chamber. Behaviors are record d as frequency of photobeam crossings.  
Figure 5. Digital photographs of the NMI analytical devices and behavioral (open-field) 




Locomotion (Ambulation) is described as continuous movement in a forward direction. Stereotypy 
is described as repeated grooming motions or Fine Movements. Central locomotion is described as 
movements into the center of the chamber which provides evidence of a reduction i  anxiety because 
rodents usually move around the corners and walls of an enclosure during natural movement. 




Thigmotaxis is the term used for corner, wall behavior. Thigmotaxis is used as a test for indicating that 
the animal is feeling anxiety. Increases in central locomotion behavior reliably determine anxiety 
reduction (36-38). Enhanced anxiety is displayed by animals who have a diminished desire to explore 
novel environments (39).  
2.10. Study Design 
NMI electrochemical signals for neurochemicals are recorded separately at distinct oxidation 
potentials, within seconds and sequentially. Recordings are repeated every five min for a period of 2 
hrs before drug(s) are administered. The first hr pre-drug, allows exploratory behavior in a novel 
environment. The second hr pre-drug allows the animl to become habituated before drug(s) are 
administered. Three points, at the end of the habitu tion period, at which time the animal no longer 
responds to external stimuli, provides the baseline for both neurochemical and behavioral data. 
2.11. Confirmation of Biosensor Placement 
Placement within NAc is confirmed by the potassium ferrocyanide blue dot method (specifications: 
current in mA, 30; time in sec, 40).  
2.12. Statistics 
One-Way Analysis of Variance (ANOVA) as studied by the PRISM program, is used to determine 
statistically significant differences in neurochemical and behavioral responses after drug(s)  
administration within and between the major groups studied. Statistical analyses within each individual 
group are performed by Tukey's post hoc tests. Alpha significance is set at the P=0.05 level.  
 
3. Results and Discussion 
3.1. Changes in neurochemicals and behavior after cocaine  
"Why do people use cocaine?" To say that addiction is a complex and poorly understood behavior is  
an understatement. Addiction is a compulsive disorder which is maintained despite tremendous adverse 
consequences. At least, recent discoveries in the field of cocaine addiction have provided some 
answers to this question, "why...? " (cf. 4, 40 for reviews). Some of these recent discoveries are: (a) 
females are more responsive to cocaine than are mals; these data have been reported in animals and 
humans (41,42), (b) the reinforcing properties of ccaine can lead to a psychosis similar to a 
schizophrenic psychosis in animals and humans; the a ypical antipsychotic medication, risperidone, 
may be a useful therapy (43), (c) serotonin plays an important role in the reinforcing effects of cocaine 
because 5-HT is known to neuromodulate DA, which is the primary reinforcer; these data are from 
animal studies (44,46) and (d) further animal studies show that there is an adenosine involvement in 
the cocaine reactions (6,48). More answers from clinical studies are forthcoming. In fact, possible 
pharmacotherapies for cocaine addiction, based on DA (45) 5-HT (46), DA transporter antagonists (47) 
and adenosine/DA coupled GPRC heteromers  (48), are in progress.  




The results from the present studies, Figure 6A and B, show that acute cocaine increases DA, 5-
HT, HVA and L-TP release in NAc of freely moving and behaving animals. Simultaneously, cocaine 
increases locomotion and stereotypy and reduces anxiety behavior. The data indicate that cocaine 
increases neurotransmitter turnover as well as releas  of neurotransmitters, metabolites and precursors 
in NAc. This NMI neurochemical and behavioral paradigm enables new insights into psychostimulant-
induced reward-related behaviors driven by reward-related brain neurotransmitters.  
NMI enables detection of neurochemicals and monitori g of behaviors in vivo before and after 
administration of cocaine in the same animal with no i terruption in spatial or temporal resolution. 
This paradigm allows for "Same Animal Control" whic provides more accurate results than was 
previously technically available. Figures 6-12 are designed to show that neurochemical and behavioral 
changes after drug(s) administration are simultaneous. The format is as follows:  Neurochemical 
effects of drug(s) on DA, 5-HT (A) and HVA and L-TP (B) in NAc of unrestained freely moving 
animals are shown by line graphs. Changes in current/concentration from baseline are reported on the y 
axes on the right (Baseline = 100%). Behavioral effects of drug(s) are shown in histogram form in (A) 
for comparison with DA and 5-HT and repeated in (B) for comparison with HVA and L-TP. Behavior 
is reported as frequency or number of times the anim l crosses the infrared photobeams in log values 
on the y axes on the left (Baselines = Central Locomotion (Ambulation) (CenA=1.3); Peripheral 
Locomotion (Peripheral Ambulations) (PerA=2.3); Stereotypy (Peripheral Fine Movements/Grooming) 
(PerF=2.0). Data are collected every five min and are presented in fifteen min intervals. 
Figure 6A and B shows the neurochemical and behavioral changes after acute cocaine 
administration (5 mg/kg, ip). Statistical Significance: Neurochemical: Anova: all 
groups; p<0.005 to p<0.0004. Tukey's post hoc analysis: DA, 5-HT and HVA increased 
above baseline (p<0.001), L-TP increased above baseline (p<0.01). Behavioral: Anova: 
all groups; p<0.0042 in first hr only; Tukey's post hoc analysis: CenA increased above 
baseline (p<0.01), PerA and PerF increased above baseline (p<0.001).  


















































































































































It is thought that acute cocaine and chronic administration produces its neurochemical and 
behavioral effects in brain reward centers by colocalized and interacting A2A/DA2 heteromeric GPRCs 
in NAc (6,48) and by mRNAs expression of main classes of G alpha proteins in NAc (49).  Increased 
DA release derived from VTA may be a factor (6, 74).  Chronic cocaine effects, on G protein signalling 
cascades, growth factors and other physiologic processes implicated in neuroplasticity in the DA 
reward mesolimbic pathway, are reviewed (50).  Chronic cocaine responses to the extracellular signal-
related kinase signalling pathway (ERK), brain deriv d neurotrophic factor (BDNF), glutamate 
transmission and synaptic plasticity are also discus ed in the latter review.  
3.2. Changes in neurochemicals and behavior after caffeine 
Unlike cocaine, which exhibits a classical pharmacologic dose-response curve in which increasing 
doses of cocaine produce correlating increasing effects, caffeine exhibits an "Inverted U Shaped 
Function of Dose".  Due to this phenomenon, caffeine's effect on DA concentrations in NAc and DStr 
are reduced at high doses (50-100 mg/kg, ip), causing an aversive feeling, possibly by DA reduction 
and/or phosphodiesterase inhibition. The low dose of caffeine (about 3-15 mg/kg ip) and the moderate 
dose of caffeine (about 25-30 mg/kg ip) have a potent DA-ergic component and are reported to be 
euphoric and reinforcing in animals and humans (cf. 51 for review). In the present studies, we focus on 
the moderate dose of caffeine because our follow-up investigations after caffeine, consists of studies of 
caffeine and cocaine co-administered and at this moderate (middle) dose, caffeine potentiates cocaine-
seeking behavior in animals (52).  
Guanine-nucleotide-binding proteins (GP) are key comp nents of cellular signalling. The first 
example of G Protein signalling, showing that a natural antagonist displays different affinities 
depending on which heteromer forms the targeted receptor,  has been provided by caffeine.  Adenosine 
A1 and A2A receptors form heteromers which alter the biochemical characteristics of the receptors, 
resulting, e.g.,  in a reduced affinity of the A1 receptor for agonists.  These two receptors and their
heteromers are expressed to a high degree in both pre-and post synaptic striatal neurons (cf 53 for  
review).  Caffeine mechanisms have been shown to be mediated by a Gs protein/A2A antagonist 
receptor reaction(54). We selected the NAc-mesolimbic rain-reward pathway to study the 
psychostimulant properties of caffeine, wherein G Protein/D1-D2 dimers have been discovered (55).    
NMI results, Figure 7A and B, show that caffeine, administered at a moderate dos , increases DA, 
5-HT, HVA and L-TP and like cocaine, caffeine increas s locomotion and stereotypy and reduces 
anxiety behavior. However, there are some interesting d fferences in the comparative results. Cocaine 
and caffeine effects on DA release in NAc parallel each other in the first hr; in the second hr, though, 
the DA response to caffeine is about 30% greater than cocaine. Serotonin release is greater in the 
caffeine group and L-TP release is dramatically greater in the caffeine group indicating that more L-TP 
is available for production of 5-HT in the caffeine group. Homovanillic acid responses to caffeine and
cocaine are similar. Caffeine's effect on locomotion and anxiety reduction is greater than that of 
cocaine and caffeine's effect on stereotypy is greate  than that of cocaine during the first hr. 
 




Figure 7A and B shows the neurochemical and behavioral changes after acute caffeine 
administration (25 mg/kg ip). Statistical Significance: Neurochemical: Anova: all 
groups; p<0.01 to p<0.0004; Tukey's post hoc analysis: DA increased above baseline 
(p<0.01), 5-HT and L-TP increased above baseline (p<0.001); HVA increased above 
baseline (p<0.05). Behavioral: Anova: all groups; p<0.0001; Tukey's post hoc analysis: 
CenA and PerA increased above baseline (p<0.01); PerF increased above baseline 
(p<0.001). 














































































































































Caffeine is a non-selective competitive blocker of A1 and A2A adenosine receptors (56,57). 
Caffeine is known to increase DA release in the mesolimbic and nigrostriatal pathways by A1 
antagonism and caffeine is known to decrease movement behavior postsynaptically by A1 antagonism 
(8, 58). Since caffeine exerted enhanced DA release in mesolimbic NAc, we can assume that this 
occurred by adenosine A1 antagonist action at NAc nerve terminals. But, in these studies, movement 
behavior increased. Hence, we may further assume that the observed increased movement behavior at 
the post-synapse may occur by a different mechanism, possibly by a stimulatory action at A2A 
receptors in concert with D2 receptor heteromers, decreasing the affinity of the D2 receptor for DA and 
DA analogues (59).  Moreover, the A1/A2A receptor heteromer is called a "sensor" for positive 
glutamate release, albeit in DStr, and high adenosine i  correlated with prevailing A2A receptors which 
inhibit A1 receptor signalling  via the heteromer (60).  
3.3. Changes in neurochemicals and behavior after cocaine and caffeine in combination 
We observed, after cocaine and caffeine were administered together, in tandem, to each animal, that 
all four neurochemicals and all three behaviors were not only dramatically increased above baseline but 
also significantly increased when comparisons were made between groups. The data are shown in 
Figure 8A and B.  
 




Figure 8A and B shows the neurochemical and behavioral actions of co-administered 
cocaine and caffeine (5 mg/kg, ip and 25 mg/kg, ip, respectively). Statistical 
Significance: Neurochemical: Anova: all groups; p<0.0001 to p<0.0004; Tukey's po t 
hoc analysis: DA, 5-HT, HVA and L-TP increased above baseline (p<0.001). All 
neurochemicals in this group were significantly greater than those produced by cocaine, 
DA (p<0.05), 5-HT, HVA, and L-TP (p<0.001). Also, 5-HT, HVA and L-TP responses 
in this group were significantly greater than those produced in the caffeine group 
(p<0.001). Behavioral: Anova: all groups; p<0.0003; Tukey's post hoc analysis: CenA, 
PerA and PerF increased above baseline (p<0.001). All behaviors were significantly 
greater than those produced by cocaine alone (p<0.001),(p<0.05)&(p<0.01) respectively.  














































































































































The effects of caffeine/cocaine on DA release in NAc of the behaving animal supercedes those of 
cocaine alone by about 40% and 60% and those of caffeine alone by about 40% and 40% in the first 
and second hrs respectively. Serotonin and HVA signals i crease about two-fold over caffeine and five 
fold over caffeine alone. L-Tryptophan responses in the combined caffeine/cocaine group were similar 
to those in the caffeine group but a four-fold increase occurred in this group compared with the cocaine 
group. Open-field behaviors also significantly increase over that produced by cocaine or caffeine alone. 
The cocaine/caffeine combination acts to a greater deg ee to reduce anxiety than does either cocaine or 
caffeine alone.  
The observed dramatic enhancements of neurochemical and behavioral effects of co-administered 
cocaine and caffeine are likely due to the formation of heterotrimeric Gq/11 G proteins which derive 
from a different signalling mechanism mediated by the D1-D2 receptor heterodimer (dimer).  In this 
dimer, Gq/11 protein forms in place of the Gi and the Gs coupled DA receptors, resulting in increased 
calcium mobilization, calmodulin kinase activation and hence, increased neurotransmitter-driven 
reward related behavior in NAc (53,55). The Gq/11 protein/DA mechanism has been reported to evoke 
neural and behavioral phenotypes with repeated cocaine dministration (61). These dramatic 
enhancements of neurochemical and behavioral effects of co-administered cocaine and caffeine are 
probably also due to caffeine's ability to enhance cocaine-seeking at the moderate dose which, 




according to the "Inverted U-Shaped Function of Caffeine Dose", exhibits the most potent DA 
response in NAc and DStr (51).      
The present data are supported by previous data from this and other laboratories with a variety of 
different behavioral assays in which caffeine was studied at the moderate dose to enhance, increase or 
potentiate the effects of cocaine (62-65). Further evidence for attributing potentiated ffects of caffeine 
on cocaine to caffeine's moderate dose, comes from data which show that low and high doses of 
caffeine are neuroprotective against cocaine-induce DA-ergic neurotoxicity (66,67). 
A2A/D2 receptors form complex receptor heteromers that arget G protein intracellular signalling 
cascades and play a role in control of movement, motor learning, motivation and brain reward 
mechanisms (68). We suggest that A2A/D2 heteromeric G-coupled complexes and/or colocalized and 
coexpressed D1/D2 Gq/11protein coupled dimers may mediate, at least in part, the potentiated 
neurochemical and behavioral responses observed when caffeine, at the moderate dose, is co-
administered with cocaine.  
3.4. Changes in neurochemicals and behavior after ketanserin 
Our aim here is to use ketanserin to help delineate the mechanism of action of cocaine. The effects 
of ketanserin on neurochemicals and behavior are shown in Figure 9A and B. 
Figure 9A and B shows the neurochemical and behavioral effects of acute ketanserin 
administration. Statistical Significance: Neurochemical: Anova: all groups; p<0.006 to 
p<0.0002; Tukey's post hoc analysis: DA and L-TP increased above baseline (p<0.001), 
5-HT and HVA increased above baseline (p<0.05). DA and 5-HT responses were 
similar to those of cocaine in the second hr. Behavioral: Anova: all groups; p<0.0082; 
Tukey's post hoc analysis: behavioral responses were unremarkable; none of the three 
behaviors (CenA, PerA and PerF) reached statistical significance over baseline. Data 
were similar to that produced by ketanserin when administered in combination with 
caffeine.  CenA for ketanserin were similar to that of the ketanserin/cocaine group.  



















































































































































As mentioned previously, there is a good rationale for the use of the antihypertensive, ketanserin, in 
this regard: (a) ketanserin is a direct receptor antagonist at 5-HT2A/2C receptors, (b) based on the high 
presence of 5-HT2A and 5-HT2C receptors in NAc (69), ketanserin is most suitable for these studies 
because our biosensor is placed in NAc and (c) serotonin is an important neurotransmitter in brain 
reward (44,46) and in the antihypertensive action of ketanserin (70).  
Results showed that DA, 5-HT, HVA and L-TP increase above baseline, but the frequency of 
behavioral events in the open-field paradigm are unremarkable after ketanserin injection. All four 
neurochemicals increase over cocaine except for DA release during the first hr. All four 
neurochemicals show lesser effects than caffeine except for the HVA response which shows an 
increase compared with caffeine during the second hr of study.  
Direct 5-HT receptor antagonists are expected to increase 5-HT release due to an action on 
autoreceptors on presynaptic 5-HT cell bodies in dorsal raphe. Dopamine release in NAc is increased 
due to neuromodulation by 5-HT; the DA response to ketanserin is a secondary response. Is adenosine 
involved? This is unclear at this time. Nonetheless, ketanserin reverses catalepsy produced by DA2
antipsychotic agents with A2A agonist activity through 5-HT receptor activation (71). What is clear,  
though, is that the 5-HT2A and 5-HT2C receptors  are Gq-coupled receptors.  Indeed, treatment with the 
5-HT agonist, (-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCL (DOI), caused a down- 
regulation of 5-HT2A receptors and a reduction in G-protein-coupled 5-HT2A receptors. The authors 
suggest that DOI causes a phosphorylation of Galphaq/11protein and thereby contributes to the 
desensitization of 5-HT2A receptors (72).  Furthermore, ketanserin, itself, is reported to bind to G 
protein: guanosine-5'-(gamma-[(35)S]thio) triphosphate in several specific neuroanatomic substrates in 
brain and ketanserin was shown to bind to this G protein particularly in NAc (73). 
3.5. Changes in neurochemicals and behavior after ketanserin and cocaine 
 All four neurochemicals and all three behaviors are ttenuated by combining ketanserin with 
cocaine compared with results from cocaine alone. Dopamine, HVA and L-TP concentrations 
essentially show a return to baseline while 5-HT release is attenuated significantly below baseline. The
data agree with previous studies wherein ketanserin antagonized locomotor behavior during cocaine 
challenge in a cocaine discrimination paradigm (74). The data also confirm previous studies from this 
laboratory wherein ketanserin attenuated the neurochemical and behavioral responses to cocaine (75). 
The data are shown in Figure 10A and B. 
Cocaine increases blood pressure and heart rate primarily through an action on the sympathetic 
nervous system while suppressing baroreflexes and vagal tone; these actions further contribute to 
cocaine-induced tachycardia (76). Cocaine produces a pressor response associated with an initial 
hindquarters vasoconstriction followed by a prolonged vasodilation in conscious rats which has been 
reported to be antagonized by β adrenoreceptor antagonists like propranolol (77).  
Ketanserin reduces blood pressure by 5-HT2 (70) and by 5-HT2 plus α1 adrenoreceptors (14). In 
sinoaortic denervated (SAD) rats and in spontaneously hypertensive rats (SHR), which have high blood 
pressure and high blood pressure variability, ketanseri  lowered both cardiovascular parameters studied 
(78). Moreover, DA is related to the pathophysiology f hypertension. There are reports that DAD1 and 




DAD2 receptors are upregulated in DStr of young, prehyprtensive rats and cholecystokinin 8S-induced 
release of DA in NAc is greater in SHR rats than in ormals (79,80).  
Figure 10A and B. shows the neurochemical and behavioral effects of ketanserin and 
cocaine (3.0 mg/kg, sc and 5 mg/kg, ip, respectively). Statistical Significance: 
Neurochemical: Anova: all groups; 5-HT decreased (p<0.0005); Tukey's post hoc 
analysis: DA, HVA and L-TP showed an insignificant change from baseline, 5-HT 
significantly decreased from baseline (p<0.001). Neurochemicals were reduced to 
baseline compared with cocaine alone i.e., DA and 5-HT (p<0.001) and L-TP (p<0.05). 
HVA was reduced compared to cocaine in the first hr. Behavioral: Anova: all groups; 
p<0.006; Tukey's post hoc analysis: CenA increased above baseline (p<0.01). PerA and 
PerF increased above baseline (p<0.001). CenA, previously produced by cocaine, were 
inhibited by ketanserin whereas PerA were inhibited by ketanserin only in the first hr. 
Ketanserin was unable to inhibit PerF produced by cocaine.   






































































































































Therefore, ketanserin may be attenuating cocaine effects through its 5-HT-ergic and DA-ergic 
antihypertensive effects as well as through its GPRC-ligand related functional selectivity. Indeed, 
recent studies in humans, using Positron Emission Tmography, have shown a high correlation 
between increased DA in DStr and increased blood pressure after administration of the cocaine-like 
psychostimulant, methylphenidate (81). We suggest that the antihypertensive properties of ketanserin 
provide a reasonable mechanism for attenuating, at leas in part, psychostimulant monoamine release 
and behavior produced by cocaine; the mechanism may occur through a 5-HT2A/2C modulated DA2 
response to cocaine with a significant role played by the family of the GPs and their heteromers.  
3.6. Changes in neurochemicals and behavior after ketanserin and caffeine 
Only three of four neurochemicals and all three open-fi ld behaviors produced by caffeine are 
attenuated by ketanserin. The data are shown in Figure 11A and B. Ketanserin did not inhibit DA 




release in NAc. On the contrary, DA release is enhanced in NAc when ketanserin and caffeine are 
administered together. This enhancement of DA releas  in NAc is surprising as unlike 
ketanserin/cocaine results, brain reward mechanisms and hypertension appear to be only partially 
inhibited. Also, it is noteworthy that enhanced DA release in NAc after ketanserin and caffeine 
administration could have adverse medical implications, since it is known that the pathophysiology of 
hypertension in SHR animals involves an increase in DA in NAc and DStr.  
Figure 11A and B shows the neurochemical and behavioral effects of acute 
ketanserin and caffeine (3.0 mg/kg, sc and 25 mg/kg, ip, respectively). Statistical 
Significance: Neurochemical: Anova: all groups: p<0.03 to p<0.008; Tukey's post hoc 
analysis: DA increased above baseline (p<0.01), 5-HT and HVA increased above 
baseline but effects were not significant, L-TP Increased above baseline (p<0.05). 
Compared with caffeine alone, there were significant decreases in 5-HT (p<0.001) and 
L-TP (p< 0.01). Behavioral: Anova: all groups: p<0.0001; Tukey's post hoc analysis: 
PerF increased over baseline (p<0.01); CenA and PerA effects were not significant. 
Compared with caffeine results, all three behaviors were significantly inhibited by 
ketanserin (p<0.01).  
















































































































































Enhancement in the DA response in NAc in this group is seen in the second hr; the DA response to 
ketanserin/caffeine is enhanced over caffeine alone by more than 30% and actually matches the 
cocaine/caffeine effect on DA release in NAc. The HVA response to ketanserin/caffeine is similar to 
that of caffeine and the L-TP response is blocked as compared to caffeine effects when caffeine is 
administered alone. The 5-HT response produced by caffeine is dramatically inhibited by ketanserin by 
about 70%.  All open-field behaviors, which increas fter caffeine, are attenuated by ketanserin.  
Ketanserin may be affecting brain reward and hypertensive mechanisms through its 5-HT-ergic and 
DA-ergic effects and downstream through GPRCs, cyclases, and kinases. Given the caveat that these 
studies are acute experiments which involve a single injection of ketanserin and caffeine, the data may  




indicate adverse reactions only to acute ketanserin and caffeine. Therefore, the data may not predict 
that adverse reactions to ketanserin and caffeine will occur during chronic administration of these 
compounds.  
3.7. Changes in neurochemicals and behavior after ketanserin, cocaine and caffeine 
These data are shown in Figure 12 A and B. When caffeine is co-administered with ketanserin and
cocaine, ketanserin continues to inhibit 5-HT release nd production of 5-HT through L-TP synthesis. 
The HVA response is inhibited to below baseline. But, DA release is enhanced as in the 
ketanserin/caffeine group. Like the ketanserin/caffeine effect, DA release reached that observed in the 
cocaine/caffeine group. As mentioned previously, enhancement of DA release in NAc could be 
worrisome as antihypertensive action has been correlated with decreased and not increased DA 
concentrations in NAc and DStr (79,80). The main difference between this group and the 
ketanserin/caffeine group lies in the open-field behavioral responses. Open-field behaviors are not 
blocked by ketanserin; instead,  open-field movement b haviors are actually increased.  
Figure 12A and B shows the neurochemical and behavioral effects of acute 
ketanserin, cocaine and caffeine (3.0 mg/kg, sc, 5 mg/kg, ip and 25 mg/kg, ip, 
respectively). Statistical Significance: Neurochemical: Anova: all group: p<0.14 to 
p<0.0006; Tukey's post hoc analysis: DA increased above baseline (p<0.01), L-TP 
increased above baseline (p< 0.05), 5-HT and HVA decreased to below baseline, not 
significant. Compared with caffeine, 5-HT and HVA were inhibited by ketanserin 
(p<0.01) (p<0.05 respectively). Compared with cocaine, 5-HT and HVA were also 
inhibited by ketanserin (p<0.001). However, L-TP is significantly higher in this 
ketanserin, cocaine and caffeine group compared with the cocaine group (p<0.001). 
Behavioral: Anova: all groups: p<0012; Tukey's post hoc analysis: CenA, PerA and 
PerF increased above baseline (p<0.002, p<0.001 and p<0.01 respectively).All 
behaviors were enhanced over those seen in the caffeine and the cocaine group.  

















































































































































The data show that ketanserin is unable to block the DA neurochemical effects of cocaine when 
caffeine is present and ketanserin is unable to block DA effects of caffeine whether or not cocaine is 
present. The mechanism for these findings is not yet known. However, it is likely that blockade of G-
coupled 5-HT2A2C receptors by ketanserin neuromodulates enhanced DA release in NAc. The increase 
in open-field behaviors, observed in this group insofar as at least increased locomotion is concerned, 
may derive from postsynaptic A2A/DA2 heteromers and/or from DA-ergic release presynaptic lly in 
VTA, similarly to what happens when cocaine affects locomotor behavior.  
Figure 13A and B shows histograms derived from hourly effects of drug(s) on DA and 

























































































* = p < 0.05
** = p < 0.01






































































































* = p < 0.05
** = p < 0.01
*** = p < 0.001
* = p < 0.05
** = p < 0.01















The composite histograms, (Figure 13A and B), depicting the neurochemical effects of each set of 
the drug(s) studied herein,  further clarify the dynamic relationship between DA and 5-HT release 
within NAc in unrestrained animals. The potentiation f the moderate dose of caffeine on cocaine 
monoamine responses is clear. The direct receptor 5-HT-ergic antagonist effect of ketanserin, per se, 
on the monoamines is also clear. That ketanserin inhibits cocaine-induced monoamines and inhibits 
only the caffeine-induced 5-HT-ergic amine aspect, is clear. Thus, ketanserin's effects on cocaine and 
caffeine, although both psychostimulants, are different. All NMI studies are performed within  
ventrolateral NAc.  Since  NMI biosensors are known for precise spatial resolution, we can assume that 
the same neuronal tissue is imaged. We can reasonably assume, then, that 5-HT-G-coupled proteins are 
acting in concert with DA and Adenosine G-coupled receptors to differentiate the neuronal 
mechanisms of cocaine, caffeine and ketanserin in NAc. 
Binding to the intracellular loops of receptors, these GPRCs and their effects on intracellular and 
extracellular signalling are providing new targets for psychostimulant therapeutics. Cocaine has been 
shown to act on G proteins and on signalling cascades in NAc, PFC and DStr (82-84) and G proteins 
have been implicated in the effects of prenatal exposure to cocaine (85). Downstream in the cascade, 
DA and cAMP-regulated phosphoprotein, Mr 32 kDa (DARPP-32) has been identified as a major 
target for DA and protein kinase A (PKA) and recently, the regulation of the specific state of DARPP-
32 phosphorylation has provided an integrated mechanism for the study of dopaminoceptive neurons; 
both cocaine and caffeine act via DARPP-32 (cf 86 for review).  
Particularly for ketanserin, ligand-directed functional selectivity as well as GPRCs, may have 
significant input. Thus, "cross-talk" between and among these cellular pathways may well underlie 
differential, unexpected results during co-administration of these psychostimulants with ketanserin.  
We plan to add molecular studies of the G-protein family and signalling cascades to our studies of 
ketanserin and psychostimulant interactions.  
4. Conclusions 
With NMI and BRODERICK PROBE® biosensors, we analyzed (a) brain mechanisms of 
psychostimulants in vivo, (b) pharmacologic treatments to attenuate the sympto s of substance abuse, 
(c) critical concentration effects of caffeine and (d) possible untoward side effects of medicinal 
compounds used with caffeine. The performance of these studies has not been possible with previous 
technologies. The animal studies, presented here, are highly contributive to science and medicine. 
Furthermore, we are in the midst of applying our biosensors in animal studies to decipher 
neurochemical mechanisms which may cause Parkinson's disease (87), cognitive dysfunction post-
operatively (88), hypotension and stroke. 
Yet, all of the aforementioned studies represent only a fascinating prelude to the promise of clinical 
trials using the BRODERICK PROBE® biosensors to diagnose epilepsy and tumor disorders in 
patients.  In fact, Drs. Kuzniecky, Doyle, Pacia, Li  and Broderick will use these inventive biosensors 
to image neurotransmitters within the neocortex of patients intraoperatively with approval from the 
Internal Review Board of the New York University (NYU) School of Medicine. 
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